Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102752 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer
A Phase 1 study of Neoplasms and Pancreatic Neoplasms, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 9
- Study locations
NCT00102752: Completed Phase 1 study of Neoplasms and Pancreatic Neoplasms, sponsored by Threshold Pharmaceuticals.
NCT00102752 is a Phase 1 study of Neoplasms and Pancreatic Neoplasms that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 47 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00102752, a Phase 1 study of Neoplasms and Pancreatic Neoplasms, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Glufosfamide
Study Locations (9)
São Paulo
- Fundação Pio XII - Hospital de Câncer de Barretos - Barretos
- Universidade Federal de São Paulo - Hospital São Paulo - São Paulo
- Hospital Israelita Albert Einstein - São Paulo
Rio Grande do Sul
- Hospital Mãe de Deus - Porto Alegre
- Hospital Nossa Senhora da Conceição - Porto Alegre
Arizona
- Arizona Cancer Center - Tucson
Indiana
- Indiana Cancer Center - Indianapolis
Kentucky
- Norton Healthcare Cancer Center - Louisville
BH
- Hospital de Doenças Cardiovasculares - Biocor - Nova Lima
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2004-12 |
| Est. Completion | 2007-07 |
| Phase | Phase 1 |
What the finished NCT00102752 record still lists
NCT00102752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00102752 lists 9 locations in 6 states (São Paulo, Rio Grande do Sul, Arizona).
Frequently Asked Questions
What is clinical trial NCT00102752 about?
NCT00102752 is a clinical study titled "Study of Safety and Efficacy of Glufosfamide in Combination With Gemcitabine in Cancer". The purpose of this study is to determine the safety of glufosfamide when administered in combination with gemcitabine.
What is the current status of trial NCT00102752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2004-12. Estimated completion is 2007-07.
What conditions does trial NCT00102752 study?
This clinical trial studies the following conditions: Neoplasms, Pancreatic Neoplasms.
What interventions are being tested in trial NCT00102752?
The interventions under investigation include: Gemcitabine (DRUG), Glufosfamide (DRUG).
Who is sponsoring clinical trial NCT00102752?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00102752 being conducted?
This trial has 9 study locations across Arizona, Indiana, Kentucky, BH, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00102752's enrollment target sits among peer trials
47 109th of 158 higher than 47 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia